LEK 8829

TargetMol
Product Code: TAR-T25656
Supplier: TargetMol
CodeSizePrice
TAR-T25656-5mg5mg£2,858.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25656-50mg50mg£5,677.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25656-100mg100mg£8,103.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
LEK 8829 is a dopamine D2 receptor antagonist and D1 receptor agonist.
CAS:
145204-78-0
Formula:
C21H25N3O4S
Molecular Weight:
415.51
Purity:
0.98
SMILES:
CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1=C[C@H](CN2C)C(=O)N(C)CC#C)c34

References

1. Milivojevic N, Krisch I, Sket D, Zivin M. The dopamine D1 receptor agonist and D2 receptor antagonist LEK-8829 attenuates reinstatement of cocaine-seeking in rats. Naunyn Schmiedebergs Arch Pharmacol. 2004 Jun;369(6):576-82. Epub 2004 May 7. PubMed PMID: 15138661. 2. Zivin M, Sprah L, Sket D. Antiparkinsonian potential of interaction of LEK-8829 with bromocriptine. Eur J Pharmacol. 1998 May 22;349(2-3):151-7. PubMed PMID: 9671092. 3. Zivin M, Sprah L, Sket D. The D1 receptor-mediated effects of the ergoline derivative LEK-8829 in rats with unilateral 6-hydroxydopamine lesions. Br J Pharmacol. 1996 Nov;119(6):1187-96. PubMed PMID: 8937722; PubMed Central PMCID: PMC1915887. 4. Glavan G, Sket D, Zivin M. Modulation of neuroleptic activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 intrinsic activity in hemi-parkinsonian rats. Mol Pharmacol. 2002 Feb;61(2):360-8. PubMed PMID: 11809861.